title: Level of DNA topoisomerase IIalpha mRNA predicts the treatment response of relapsed acute leukemic patients.
abstract: The DNA topoisomerase IIalpha (Topo IIalpha) is known as a target enzyme for many chemotherapeutic agents. We investigated the Topo IIalpha mRNA expression by real-time RT-PCR in 37 paired samples at diagnosis and at relapse of acute leukemic patients in relation to drug sensitivity and clinical outcome. The Topo IIalpha levels in leukemic blasts at relapse were significantly higher than that at diagnosis, especially in ALL. The increase in the Topo IIalpha level at relapse was significant in cases which could not achieve a second remission, but not significant in cases which achieved a second remission. These results suggest that the change of Topo IIalpha expression in leukemic blasts at relapse may predict therapeutic responsiveness.
authors.affiliation: Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan.
authors.forename: Yan-Hua
authors.initials: YH
authors.lastname: Wang
authors.forename: Minoko
authors.initials: M
authors.lastname: Takanashi
authors.forename: Kazue
authors.initials: K
authors.lastname: Tsuji
authors.forename: Norina
authors.initials: N
authors.lastname: Tanaka
authors.forename: Masayuki
authors.initials: M
authors.lastname: Shiseki
authors.forename: Naoki
authors.initials: N
authors.lastname: Mori
authors.forename: Toshiko
authors.initials: T
authors.lastname: Motoji
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000235:genetics*; D001752:Blast Crisis; D002453:Cell Cycle / Q000187:drug effects; D004250:DNA Topoisomerases, Type II / Q000235:genetics*; D004268:DNA-Binding Proteins / Q000235:genetics*; D003630:Daunorubicin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics*; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000201:enzymology / Q000235:genetics; D011110:Polymorphism, Genetic / Q000235:genetics*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics*; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics* / Q000378:metabolism; D012074:Remission Induction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000903:Antibiotics, Antineoplastic; D000951:Antigens, Neoplasm; D004268:DNA-Binding Proteins; D012333:RNA, Messenger; D004250:DNA Topoisomerases, Type II; D003630:Daunorubicin